ANI PHARMACEUTICALS, INC Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ANI PHARMACEUTICALS, INC stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $308.00K, a 75.18% decline year-over-year.
- ANI PHARMACEUTICALS, INC stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $2.20M, a 13.10% decline year-over-year.
- ANI PHARMACEUTICALS, INC stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $38.00K, a 97.76% decline year-over-year.
- ANI PHARMACEUTICALS, INC stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $9.79M, a 720.62% increase year-over-year.
- ANI PHARMACEUTICALS, INC stock issued during period, value, stock options exercised for fiscal 2025 was $13.60M, a 109.68% increase from fiscal 2024.
- ANI PHARMACEUTICALS, INC stock issued during period, value, stock options exercised for fiscal 2024 was $6.49M, a 27.88% decline from fiscal 2023.
- ANI PHARMACEUTICALS, INC stock issued during period, value, stock options exercised for fiscal 2023 was $9.00M, a 517.01% increase from fiscal 2022.
- ANI PHARMACEUTICALS, INC stock issued during period, value, stock options exercised for fiscal 2022 was $1.46M, a 29.53% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $308.00K 10-Q · filed 2026-08-07 | $12.34M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $2.20M 10-Q · filed 2026-05-08 | $13.27M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $38.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $13.60M 10-K · filed 2026-02-27 |
| 2025-09-30 | $9.79M 10-Q · filed 2025-11-07 | $15.27M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $1.24M 10-Q · filed 2026-08-07 | $6.67M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $2.53M 10-Q · filed 2026-05-08 | $6.43M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $6.49M 10-K · filed 2026-02-27 |
| 2024-09-30 | $1.19M 10-Q · filed 2025-11-07 | $6.76M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $1.00M 10-Q · filed 2025-08-08 | $11.15M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $2.59M 10-Q · filed 2025-05-09 | $11.43M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $1.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $9.00M 10-K · filed 2026-02-27 |
| 2023-09-30 | $5.58M 10-Q · filed 2024-11-08 | $7.79M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $1.29M 10-Q · filed 2024-08-06 | $2.70M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $157.00K 10-Q · filed 2024-05-10 | $1.61M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $768.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $1.46M 10-K · filed 2025-02-28 |
| 2022-09-30 | $483.00K 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $203.00K 10-Q · filed 2023-08-09 | |
| 2022-03-31 | $3.00K 10-Q · filed 2023-05-08 | |
| 2021-12-31 | $2.07M 10-K · filed 2024-02-29 | |
| 2015-12-31 | $819.00K 10-K · filed 2018-02-27 | |
| 2014-12-31 | $819.00K 10-K · filed 2017-03-02 | |
| 2011-12-31 | $32.44K 10-K · filed 2013-02-28 | |
| 2010-12-31 | $2.01K 10-K · filed 2013-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |